Recent investigations have centered on the overlap of GLP|GIP|glucagon receptor agonist therapies and dopaminergic neurotransmission. While GLP activators are commonly employed for addressing type 2 diabetes mellitus, their unexpected consequences on motivation circuits, specifically governed by dopaminergic pathways, are gaining significant intere